Skip to main content
REGN
NASDAQ Life Sciences

FDA Approves Livsayis, First siRNA Therapy for Generalized Myasthenia Gravis

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$942
Mkt Cap
$97.797B
52W Low
$591.52
52W High
$991.73
52W Position info
59% above low
Off High info
5.0% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

REGN sits 59% above its 52-week low of $591.52.

Summary

The FDA approved Livsayis (cemdisiran), making it the first and only siRNA therapy for generalized myasthenia gravis and the only gMG treatment dosed subcutaneously four times a year. That dosing schedule is the commercial hook — it undercuts the frequent-infusion and daily-oral regimens patients currently face in a chronic neuromuscular disease. Regeneron will sell it only through a Livsayis REMS program, which adds distribution friction but is common for biologics of this type. The approval lands on top of a strong run: Q3 revenue grew 36% to $5.1 billion with record Dupixent sales, and the October Sanofi amendment added four antibodies to the pipeline. No launch timing, pricing, or peak-sales guidance was disclosed in the release.

At the time of this announcement, REGN was trading at $942.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $97.8B. The 52-week trading range was $591.52 to $991.73. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

REGN - Latest Insights

REGN
Nov 08, 2026, 4:00 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $900.00
Real-time Price: $942.00 info
Change: +$42.00 (+5%) info
Market Cap: $97.797B info
REGN
Oct 30, 2026, 12:34 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $910.52
Real-time Price: $942.00 info
Change: +$31.48 (+3%) info
Market Cap: $97.797B info
REGN
Oct 30, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $856.00
Real-time Price: $942.00 info
Change: +$86.00 (+10%) info
Market Cap: $97.797B info
REGN
Oct 30, 2026, 6:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $835.00
Real-time Price: $942.00 info
Change: +$107.00 (+13%) info
Market Cap: $97.797B info
REGN
Oct 12, 2026, 12:06 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $764.45
Real-time Price: $942.00 info
Change: +$177.55 (+23%) info
Market Cap: $97.797B info